Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe

Richard P. Steeds, MD; Matthias Lutz, MD; Jeetendra Thambrajah, MD; Antonio Serra, MD; Eberhard Schulz, MD; Jiri Maly, MD; Marco Aiello, MD; Tanja K. Rudolph, MD; Guy Lloyd, MD; Alessandro Santo Bortone, MD; Karl Eugen Hauptmann, MD; Alberto Clerici, MD; Georg Delle-Karth, MD; Johannes Rieber, MD; Ciro Indolfi, MD; Massimo Mancone, MD; Loic Belle, MD; Alexander Lauten, MD; Martin Arnold, MD; Berto J. Bouma, MD; Cornelia Deutsch, MD; Jana Kurucova, MD; Martin Thoenes, MD; Peter Bramlage, MD; Norbert Frey, MD; David Messika-Zeitoun, MD

Background—Many patients with severe aortic stenosis are referred late with advanced symptoms or inappropriately denied intervention. The objective was to investigate whether a structured communication to referring physicians (facilitated data relay) might improve the rate and timeliness of intervention.

Methods and Results—A prospective registry of consecutive patients with severe aortic stenosis at 23 centers in 9 European countries with transcatheter as well as surgical aortic valve replacement being available was performed. The study included a 3-month documentation of the status quo (phase A), a 6-month intervention phase (implementing facilitated data relay), and a 3-month documentation of a legacy effect (phase-B). Two thousand one hundred seventy-one patients with severe aortic stenoses were enrolled (phase A: 759; intervention: 905; phase-B: 507). Mean age was 77.9 ± 10.0 years, and 80% were symptomatic, including 52% with severe symptoms. During phase A, intervention was planned in 464/696 (67%), 138 (20%) were assigned to watchful waiting, 8 (1%) to balloon aortic valvuloplasty, 60 (9%) were listed as not for active treatment, and in 26 (4%), no decision was made. Three hundred sixty-three of 464 (78%) patients received the planned intervention within 3 months. Timeliness of the intervention improved as shown by the higher number of aortic valve replacements performed within 3 months (59% versus 51%, P = 0.002) and a significant decrease in the time to intervention (36 ± 38 versus 30 ± 33 days, P = 0.002).

Conclusions—A simple, low-cost, facilitated data relay improves timeliness of treatment for patients diagnosed with severe aortic stenosis, resulting in a shorter time to transcatheter aortic valve replacement. This effect was mainly driven by a significant improvement in timeliness of intervention in transcatheter aortic valve replacement but not surgical aortic valve replacement.

Clinical Trial Registration—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02241447. (J Am Heart Assoc. 2019;8:e013160. DOI: 10.1161/JAHA.119.013160.)

Key Words: Quality of care • aortic stenosis • transcatheter aortic valve implantation • surgical aortic valve replacement • facilitated data relay

Aortic stenosis (AS) is a progressive, life-threatening valve disorder that is characterized by a rapid increase in risk of sudden death once symptoms appear.1 Despite clear American and European guidelines on management,2–5 there is evidence that gaps between current recommendations and actual clinical practice exist.6–9 Patients with severe symptomatic AS may be referred late with advanced symptoms or inappropriately denied intervention.7,8,10 Patients managed in an inappropriate or untimely way incur excess morbidity and mortality, not only because of the risk of “death on the waiting list” but also from increased perioperative complications and incomplete recovery.11,12 It is therefore important to identify ways of improving the timeliness of healthcare delivery for patients with AS.

Lack of awareness of the condition and of its consequences may represent a potentially important reason for the undertreatment observed in patients with valvular heart disease. In a recent community-based study,13 although echocardiography correctly identified the disease and its severity, a significant proportion of the patients were left...
Clinical Perspective

What Is New?

- Many patients with severe aortic stenosis are referred late with advanced symptoms or inappropriately denied intervention.
- A simple, low-cost, facilitated data relay improves timeliness of treatment for patients diagnosed with severe aortic stenosis, resulting in a shorter time to transcatheter aortic valve replacement.

What Are the Clinical Implications?

- Facilitated data relay has the potential to reduce perioperative and postoperative morbidity, while decreasing the number of patients dying on the waiting list for aortic valve replacement.
- Future studies are now needed to formally demonstrate the impact of facilitated data relay on outcome.

Methods

Study Design and Site Selection

IMPULSE was a prospective, multinational registry of patients with severe AS in Europe, the rationale and design of which has been described recently. In brief, IMPULSE evaluated the effect of a nurse-led FDR on the timing and rate of valve procedures. A total of 23 centers from 9 countries (Austria, Czech Republic, France, Germany, Italy, The Netherlands, Spain, Switzerland, and the United Kingdom) were involved, with patients enrolled between March 2015 and April 2017.

The sites were selected on the basis that each offered the full range of treatment options for AS, including surgical and transcatheter procedures, the rationale being that these might provide the best picture of service delivery. Although the 2012 guidelines applied during the conduct of the study, the results were considered against the background of the 2017 European Society of Cardiology and 2017 American College of Cardiology guidelines. The study was carried out in accordance with the Declaration of Helsinki, was approved by the independent ethics review board at each participating institution, and patient informed consent was obtained. The data that support the findings of this study are available from the corresponding author upon reasonable request.

The study had 3 phases: baseline observation phase A, to document the management of patients with severe AS enrolled during a 3-month period; FDR intervention phase, to evaluate the efficacy of the FDR intervention among patients enrolled during the subsequent 6-month period; and follow-up observation phase B, to evaluate any legacy effect of the FDR intervention among patients enrolled during a final 3-month period (Figure 1). During the intervention phase, the study nurse contacted the referring physician within 7 days to implement the FDR. During the 2 observation phases, there was no contact with the referring physicians. Follow-up for all patients was capped at 3 months, when details of any treatment during the period were collected.

Patients

Patients over 18 years of age were included in the registry based on a new finding at echocardiography of native severe AS, whether symptomatic or asymptomatic. A diagnosis of severe AS was defined as 1 or more of the following findings on echocardiography: an aortic valve area of <1 cm² (computed using a continuity equation), an indexed aortic valve area of <0.6 cm²/m², a maximum jet velocity of >4 m/s, or a mean transvalvular gradient of >40 mm Hg. Patients were excluded if they had prior aortic valve intervention.

Intervention: FDR

A study nurse was used at each center to monitor echocardiography results. During the first observational phase, the communication between the hospitals and referring physicians relied on usual practice in each center (eg, via a standard report or electronic discharge letter provided to the office-based physician). This letter commonly summarizes any clinical findings, may give recommendations for further investigations but is not highlighted, may potentially not be reviewed in a timely fashion, and there may be no mechanism in place to record appropriate action.

During the intervention phase, the nurse contacted the relevant referring physician in addition to the aforementioned measures for each center and about 1 week after a patient was enrolled, to inform them that their patient had been diagnosed with severe AS on echocardiography (FDR) and had consented to participation in a study assessing follow-up of patients with severe AS. The FDR outlined the class 1 indications for intervention in severe AS and gave all possible management options, without recommending a specific technique (transcatheter aortic valve replacement [TAVR] or surgical aortic...
valve replacement (SAVR) over one another. Physicians and/or patients were contacted again 3 months later to collect details of the actual treatment given. Contact was made via a structured email, fax, or when necessary, by telephone call. A standard format was used for all communications.

**Data Collection**

Data collected at baseline for all patients included demographics, medical history, and symptoms (chest pain, shortness of breath, and dizziness on exertion/syncope). Severe symptoms were defined as the presence of Canadian Cardiovascular Society class III or IV angina, New York Heart Association functional class III or IV, and/or dizziness on exertion/syncope. The logistic EuroScore I and the EuroScore II were calculated as an indication of surgical risk. Frailty was assessed according to the ability of the patient to walk 5 meters in <6 s and to perform activities of daily living.16 Activities of daily living and life expectancy were assessed by the dedicated nurses or physicians, but no specific list of activities of daily living or risk calculator was recommended. The results of the echocardiographic assessment were recorded, including the presence of...

---

**Figure 1.** Facilitated data relay. FU (follow-up) indicates 3 months follow-up period where effects of a potential intervention are collected and performance/nonperformance of an intervention are documented; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

**Figure 2.** Patient flow across phases. FU (follow-up) indicates 3 months follow-up period where effects of a potential intervention are collected and performance/nonperformance of an intervention are documented. Full FU refers to data available.
coexisting aortic regurgitation, mitral or tricuspid valve disease; transvalvular gradient; left ventricle dimensions; and left ventricular ejection fraction.

At 3 months after enrollment, information on vital status (alive/dead), treatment decisions (SAVR, TAVR, balloon aortic valvuloplasty [BAV], active decision not to treat, or watchful waiting/further diagnostics) and the number of interventions performed were documented for all patients enrolled into the study. Watchful waiting was defined as the scheduling of further patient follow-up. Data were entered into a standardized electronic case report form by a dedicated study nurse. The primary outcome measure was the rate of planned and performed SAVR or TAVR within 3 months and the time to intervention.

### Statistical Analysis

Data are presented descriptively, using means with SD, medians with interquartile ranges, or absolute values with percentages. Comparisons between patients enrolled during the FDR phase or observation phase B and observation phase A were made using a Pearson $\chi^2$ or Fisher exact test for categorical variables, and a $t$ test, Mann–Whitney–Wilcoxon rank sum test, or ANOVA for continuous variables. A $P$ value of $<0.05$ was considered statistically significant.

### Table 1. Patient Characteristics

|                        | Total (n=2171) | Observation A (n=759) | Facilitated Data Relay (n=905) | Observation B (n=507) | $P$ Value for Comparison Across Phases |
|------------------------|---------------|-----------------------|-------------------------------|-----------------------|---------------------------------------|
| **Age, y**             | 77.9±10.0     | 77.6±10.2             | 78.0±9.5                      | 78.1±10.5             | 0.520                                 |
| **Female sex**         | 1041/2171 (48)| 360/759 (47)          | 436/905 (48)                  | 245/507 (48)          | 0.938                                 |
| **BMI, kg/m²**         | 27.4±5.3      | 27.4±5.8              | 27.2±4.8                      | 27.7±5.5              | 0.258                                 |
| **Symptoms**           |               |                       |                               |                       |                                       |
| Chest pain             | 487/2076 (24) | 166/726 (23)          | 201/873 (23)                  | 120/477 (25)          | 0.606                                 |
| Shortness of breath    | 1576/2123 (74)| 548/744 (74)          | 645/888 (73)                  | 383/491 (78)          | 0.084                                 |
| Dizziness on exertion/syncope | 471/1941 (24) | 157/679 (23)          | 210/835 (25)                  | 104/427 (24)          | 0.657                                 |
| NYHA class III or IV   | 859/2142 (40) | 315/755 (42)          | 338/900 (38)                  | 206/487 (42)          | 0.120                                 |
| Angina CCS class III or IV | 91/1901 (5)  | 45/676 (7)            | 29/788 (4)                    | 17/437 (4)            | 0.018                                 |
| Symptomatic*           | 1743/2171 (80)| 605/759 (80)          | 717/905 (79)                  | 421/507 (83)          | 0.199                                 |
| Severe symptoms        | 1122/2171 (52)| 402/759 (53)          | 455/905 (50)                  | 265/507 (52)          | 0.526                                 |
| **Echocardiographic valve-related parameters** | | | | | |
| Aortic valve area, cm² | 0.73±0.2      | 0.74±0.2              | 0.73±0.2                      | 0.72±0.2              | 0.323                                 |
| Indexed aortic valve area, cm²/m² | 0.40±0.1 | 0.40±0.1              | 0.40±0.1                      | 0.39±0.1              | 0.312                                 |
| Maximum jet velocity, m/s | 4.3±0.7   | 4.3±0.7               | 4.3±0.6                       | 4.3±0.7               | 0.724                                 |
| Mean transvalvular gradient, mm Hg | 47.1±14.7 | 47.2±15.0             | 47.6±14.0                     | 46.2±14.7             | 0.237                                 |
| LVH (>12 mm thick)     | 1324/2132 (62)| 490/758 (65)          | 560/902 (62)                  | 274/472 (58)          | 0.068                                 |
| EF, %                  | 55.8±12       | 56.0±12               | 56.5±12                       | 54.4±11               | 0.008                                 |
| >50%                   | 1492/2054 (73)| 520/720 (72)          | 634/854 (74)                  | 338/480 (70)          | 0.245                                 |
| 30–50%                 | 496/2054 (24)| 174/720 (24)          | 191/854 (22)                  | 131/480 (27)          |                                        |
| <30%                   | 66/2054 (3)   | 26/720 (4)            | 29/854 (3)                    | 11/480 (2)            |                                        |
| PAP, mm Hg             | 39.4±13       | 39.4±13               | 40.1±13                       | 38.2±13               | 0.098                                 |
| Frailty (severe)*      | 110/2141 (5)  | 55/755 (7)            | 33/899 (4)                    | 22/487 (5)            | 0.003                                 |
| **Surgical risk**      |               |                       |                               |                       |                                       |
| Logistic EuroScore I, %| 15.6±13.9     | 15.9±13.8             | 16.3±14.5                     | 14.1±12.9             | 0.157                                 |
| Logistic EuroScore II, %| 4.0±5.0      | 3.9±5.0               | 4.1±4.7                       | 4.1±5.4               | 0.710                                 |

Comparisons were analyzed using Pearson $\chi^2$ or Fisher exact test for categorical variables, and ANOVA for continuous variables. BMI indicates body mass index; CCS, Canadian Cardiovascular Society; EF, ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; PAP, pulmonary artery pressure.

*Defined as 1 or more cardiac symptoms presumably related to severe aortic stenosis (chest pain, shortness of breath, dizziness on exertion/syncope).

†Defined as inability to perform 2 or more activities of daily life.
analysis was performed using SPSS Version 23.0 (IBM Corp., Armonk, NY).

Results

Patient Characteristics

A total of 2171 patients with severe AS were enrolled (759 in observation phase A, 905 in the FDR intervention phase, and 507 in observation phase B; Figure 2). Of those, 1562 patients were referred by cardiologists, 273 by general physicians, 111 by cardiac surgeons, 32 by geriatricians, and 192 by other physicians (1 unknown). During the study, 44 patients were lost to follow-up (data completeness at 3 months 98.0%) and 127 patients died (death rate 5.9%) including postoperative death. The mean age of the overall (n=2171) study population was 77.9±10.0 years, and 80% had symptomatic AS including 52% with severely limiting symptoms. Echocardiography revealed a mean aortic valve area of 0.73±0.2 cm², mean indexed aortic valve area of 0.40±0.1 cm²/m², mean maximum jet velocity of 4.3±0.7 m/s, and mean transvalvular gradient of 47.1±14.7 mm Hg. The mean EuroScore II was 4.0±5.0%.

Patients enrolled in the different study phases had similar demographic and disease characteristics, apart from a slightly higher proportion of patients with angina pectoris Canadian Cardiovascular Society class III/IV and severe frailty in observation phase A, and a slightly lower mean ejection fraction.

Figure 3. Proportion of AVR (total), TAVR or SAVR planned (A) and performed (B) in all patients AND planned (C) and performed (D) in symptomatic patients within 3 months during the 3 study phases. AVR indicates aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

DOI: 10.1161/JAHA.119.013160

Journal of the American Heart Association
fraction among patients enrolled in observation phase B (Table 1). Specifically, the rate of symptomatic patients and patients presenting with severe symptoms was not different across the different phases.

**Rate and Timeliness of Intervention for AS**

During observation phase A, which was designed to demonstrate the status quo at each participating hospital before the introduction of FDR (baseline), an AVR was planned in 464/696 (67%) patients (Figure 3A planned; Figure 3B performed). Of these 464, the plan was for the majority to undergo TAVR (n=306) and fewer to undergo SAVR (n=158). Of the remaining patients identified with severe AS, 138 (20%) were considered suitable for watchful waiting, 8 (1%) were planned for balloon aortic valvuloplasty, 60 (9%) were listed as not for active treatment, and in 26 (4%), no decision was made at all. Data for the subgroup of symptomatic patients are displayed in Figure 3C and 3D. In total, 363/464 of patients (78% of the overall population) received the planned intervention within 3 months at a mean of 36±38 days in total (Figure 4A) and 36±37 days in symptomatic patients (Figure 4C).

**Effect of FDR**

During the intervention (FDR) phase B, there was a trend toward an increase in the number of AVRs planned compared with the observation phase, although this did not reach statistical significance (583/825, 71% versus 464/696, 67%, P=0.093; Figure 3A). There was no correlation between the timeliness of the FDR and the actual date of the intervention (Pearson r=0.090). There were also no differences between contact methods (phone, email/fax, or letter) for the time to intervention except for those who were referred from a physician within the hospital (P=0.001). FDR did not alter the ratio of patients listed for TAVR as opposed to SAVR. However, timeliness of the intervention improved as shown by the higher number of AVR performed within 3 months (59% versus 51%, P=0.002; Figure 3B) and a significant decrease in the time to intervention by 6 days (36±38 versus 30±33 days, P=0.002) (Figure 4A). Interestingly, this effect was mainly driven by a significant improvement in timeliness of intervention in TAVR but not in SAVR (Figures 3 and 4). Of interest, the effect of FDR was seen whether patients were symptomatic or not (Figure 3B and 3D).

We performed a time-to-event analysis for the overall AVR group as well as for those undergoing TAVI and SAVR, respectively. The time-to-intervention (if we consider it an event) was significantly reduced for the overall AVR analysis when the intervention phase was compared with the observational phase A with a P=0.002 using a log-rank and <0.001 using the Breslow test. This was seen when comparing observational phase B to observational phase A (P=0.188 and 0.257, respectively) (Figure 4B). If the time-to-event analysis is repeated for the TAVI and SAVR groups, the results reproduce the prior findings using the t test. While there is a significant effect of FDR on the rate of TAVI (P=0.011 log-rank
P = 0.001 Breslow), there is no such effect for SAVR alone (P = 0.066 log-rank, P = 0.134 Breslow). Comparisons of observational phase B to A are again not statistically significant.

**FDR: A Legacy Effect?**

Once FDR was discontinued, there was little “legacy effect.” Comparing observation phase B with observation phase A, there was neither a difference in the number of AVRs planned (332/479, 69% versus 464/696, 67%) nor in the number of AVR performed within 3 months (54.9% versus 51.3%, P = 0.223) (Table 2 and Figure 3B). Overall, time to intervention was not different between phase B and phase A (34±33 versus 36±38 days, P = 0.816) (Figure 4A).

**Facilitated Data Relay: An International Comparison**

Results were then investigated to determine whether there was a difference in effect of FDR between countries. Within each of the countries studied, there was an increase in the number of AVRs performed (Table 3), and, as a result, a consistent reduction in the time to intervention (Table 4). Within each single country, there was no significant difference in the effect of FDR, presumably because of lower power. The data from individual countries, however, together with sensitivity analysis revealed 3 important further differences. First, the percentage of cases planned (Figure S1) and then actually performed (Figure S2) within 3 months differs between countries, with a much higher percentage of definitive treatment delivered in a timely fashion (Figure S3) within 3 months in Germany compared with the United Kingdom. Second, sequentially excluding 1 country and restricting analysis to the 4 remaining countries, much of the effect of FDR appears to be delivered by analyses that include the United Kingdom and the impact loses significance when the United Kingdom was excluded. Third, there was a strong increase in the rate of AVR performance in Italy, which further increased in the second observational phase for AVR and SAVR in particular.

**Discussion**

In patients diagnosed with severe AS on echocardiography, 1 in 5 patients wait >3 months from time of diagnosis to intervention. This delay to intervention occurred despite >80% of patients being symptomatic, with the majority of these having severe limitations, classified as New York Heart Association or Canadian Cardiovascular Society class III or IV. Moreover, the delay to intervention occurred in hospitals in which both SAVR and TAVR were available on-site, where one might expect intervention to occur in a timelier fashion. A simple, low cost, and easily applicable FDR intervention

| Table 2. Treatment Actually Performed After 3 Months |
|-----------------------------------------------|
| **Observation A (n=696)** | **FDR (n=825)** | **Observation B (n=479)** |
| Total | | |
| AVR performed within 3 mo | 357 (51.3) | 487 (59.0) | 0.002 | 263 (54.9) | 0.223 |
| If AVR not performed | | |
| Date of AVR set | 41 (5.9) | 32 (3.9) | 0.067 | 23 (4.8) | 0.419 |
| Date of AVR not set | 66 (10) | 64 (8) | 0.231 | 46 (10) | 0.945 |
| TAVR | | |
| TAVR performed within 3 mo | 239 (34.3) | 334 (40.5) | 0.014 | 173 (36.1) | 0.530 |
| If TAVR not performed | | |
| Date of TAVR set | 29 (4.2) | 17 (2.1) | 0.017 | 14 (2.9) | 0.264 |
| No date of TAVR set | 38 (5.5) | 31 (3.8) | 0.112 | 24 (5.0) | 0.735 |
| SAVR | | |
| SAVR performed within 3 mo | 118 (17.0) | 153 (19) | 0.419 | 90 (18.8) | 0.418 |
| If SAVR not performed | | |
| Date of SAVR set | 12 (1.7) | 15 (2) | 0.890 | 9 (1.9) | 0.844 |
| No date of SAVR set | 28 (4) | 33 (4) | 0.982 | 22 (4.6) | 0.634 |

Comparisons were analyzed using Pearson χ² or Fisher exact test. AVR indicates aortic valve replacement; BAV, balloon aortic valvuloplasty; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement. Number of patients in whom BAV was performed within 3 months: 5/696 (0.7%) during observation phase A; 6/825 (0.7%) during intervention (facilitated data relay) phase; and 7/479 (1.5%) during observation phase B.
Table 3. Treatment Planned, and Treatment Actually Performed After 3 Months: Country-Specific Analysis

|           | Total | Observation A | Facilitated Data Relay | Observation B |
|-----------|-------|---------------|-------------------------|---------------|
|           | n (%) | n (%)         | P vs Phase A            | n (%)         | P vs Phase A |
| **Germany** |       |               |                         |               |
| AVR       |       |               |                         |               |
| Planned   | 472 (90.8) | 169 (88.5) | 191 (91.4) | 0.333 | 112 (93.3) | 0.158 |
| Performed | 449 (86.3) | 164 (85.9) | 181 (86.6) | 0.830 | 104 (86.7) | 0.842 |
| TAVR      |       |               |                         |               |
| Planned   | 390 (75.0) | 137 (71.7) | 153 (73.2) | 0.741 | 100 (83.3) | 0.019 |
| Performed | 374 (71.9) | 134 (70.2) | 147 (70.3) | 0.969 | 93 (77.5) | 0.156 |
| SAVR      |       |               |                         |               |
| Planned   | 82 (15.8)  | 32 (16.8)  | 38 (18.2)  | 0.707 | 12 (10.0)  | 0.096 |
| Performed | 75 (14.4)  | 30 (15.7)  | 34 (16.3)  | 0.878 | 11 (9.2)   | 0.097 |
| **UK**    |       |               |                         |               |
| Planned   | 247 (51.7) | 92 (51.7)  | 62 (54.4)  | 0.652 | 93 (50.0)  | 0.748 |
| Performed | 135 (28.2) | 48 (27.0)  | 42 (36.8)  | 0.075 | 45 (24.2)  | 0.544 |
| TAVR      |       |               |                         |               |
| Planned   | 143 (29.9) | 51 (28.7)  | 41 (36.0)  | 0.189 | 51 (27.4)  | 0.794 |
| Performed | 83 (17.4)  | 27 (15.2)  | 29 (25.4)  | 0.030 | 27 (14.5)  | 0.861 |
| SAVR      |       |               |                         |               |
| Planned   | 104 (21.8) | 41 (23.0)  | 21 (18.4)  | 0.347 | 42 (22.6)  | 0.918 |
| Performed | 52 (10.9)  | 21 (11.8)  | 13 (11.4)  | 0.918 | 18 (9.7)   | 0.513 |
| France    |       |               |                         |               |
| Planned   | 271 (76.1) | 83 (77.6)  | 150 (74.3) | 0.520 | 38 (80.9)  | 0.648 |
| Performed | 241 (67.7) | 71 (66.4)  | 133 (65.8) | 0.928 | 37 (78.7)  | 0.123 |
| TAVR      |       |               |                         |               |
| Planned   | 150 (42.1) | 42 (39.3)  | 83 (41.1)  | 0.754 | 25 (53.2)  | 0.108 |
| Performed | 133 (37.4) | 33 (30.8)  | 76 (37.6)  | 0.235 | 24 (51.1)  | 0.017 |
| SAVR      |       |               |                         |               |
| Planned   | 121 (34.0) | 41 (38.3)  | 67 (33.2)  | 0.366 | 13 (27.7)  | 0.202 |
| Performed | 108 (30.3) | 38 (35.5)  | 57 (28.2)  | 0.186 | 13 (27.7)  | 0.340 |
| Italy     |       |               |                         |               |
| Planned   | 242 (74.0) | 77 (71.3)  | 105 (72.4) | 0.845 | 60 (81.1)  | 0.133 |
| Performed | 198 (60.6) | 51 (47.2)  | 91 (62.8)  | 0.014 | 56 (75.7)  | <0.001 |
| TAVR      |       |               |                         |               |
| Planned   | 169 (51.7) | 60 (55.6)  | 78 (53.8)  | 0.781 | 31 (41.9)  | 0.070 |
| Performed | 133 (40.7) | 38 (35.2)  | 68 (46.9)  | 0.062 | 27 (36.5)  | 0.857 |
| SAVR      |       |               |                         |               |
| Planned   | 73 (22.3)  | 17 (15.7)  | 27 (18.6)  | 0.550 | 29 (39.2)  | <0.001 |
| Performed | 65 (19.9)  | 13 (12.0)  | 23 (15.9)  | 0.389 | 29 (39.2)  | <0.001 |

Continued
resulted in a greater proportion undergoing treatment within 3 months, mainly because of faster delivery of TAVR. FDR did not affect the rate of AVR. Delay to delivery of treatment differs between the countries included, with fewer receiving treatment within 3 months of a decision in the United Kingdom and a particular improvement with FDR in Italy. Delay between the diagnosis of severe AS and an appropriate intervention is responsible for patients dying while waiting for an intervention and can increase perioperative and late complications.11,12 Given the impact of unduly delayed intervention, the introduction of methods such as FDR that do reduce delays in management should be mandated. This is particularly important in patients with severe AS who have advanced disease at a stage when full recovery can no longer be guaranteed.6–8,17 In the current study, 52% of patients had severely limiting symptoms and 27% had an ejection fraction of \( \leq 50\% \) at the time of enrollment. Since the prognosis is poor for such patients with severe AS who do not receive appropriate treatment,18–20 a failure to deliver outcome-modifying treatment in 1 in 5 patients within 3 months suggests that there is an urgent need to improve quality of care. It is also noteworthy that consistently across all phases of the study, no decision was made regarding management of these high-risk patients in 3% to 4% of cases. Given the risk of sudden cardiac death, irreversible myocardial damage, and development of congestive heart failure, which directly impact outcome, any intervention that can speed up management pathways should lead to improved outcomes, and in large populations, may reduce mortality.

There is a consensus that the best care for patients with valvular heart disease is provided by a specialist heart valve service.21,22 One study showed that symptoms were detected earlier among patients with severe AS followed up in a structured valve clinic compared with those referred from other services, which facilitated optimized timing of surgery.23 Such services do not have to be physician-led. For example, the introduction of a sonographer-led heart valve clinic increased the proportion of patients with valvular disease managed according to best-practice guidelines from 41% to 92%.24 In our study, a simple communication by a nurse resulted in faster delivery of treatment in centers that had fully capable facilities available and which one would expect should already deliver the highest quality of care. A nurse was used in the study; however, the FDR communication itself highlighted the diagnosis, the indications for intervention, and asked for options regarding management, and so could potentially be carried out automatically or by nonmedical staff. All healthcare systems are currently under financial constraint and FDR is a low-cost intervention that was shown in this study to improve timeliness of care in AS.

Comparisons were analyzed using Pearson \( \chi^2 \) or Fisher exact test. No adjustment for multiple testing was made, because the analyses are meant to explore the country-specific effect, but with lower statistical power compared with the main analysis. AVR indicates aortic valve replacement; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

|                      | Total | Observation A | Facilitated Data Relay | Observation B |
|----------------------|-------|---------------|------------------------|---------------|
|                      | n (%) | n (%)         | P vs Phase A           | n (%)         | P vs Phase A |
| Others               |       |               |                        |               |
| n=319                | n=112 | n=155         |                        | n=52          |
| AVR                  |       |               |                        |               |
| Planned              | 147 (46.1) | 43 (38.4)      | 75 (48.4)               | 29 (55.8)     | 0.037       |
| Performed            | 84 (26.3) | 23 (20.5)       | 40 (25.8)               | 21 (40.4)     | 0.008       |
| TAVR                 |       |               |                        |               |
| Planned              | 47 (14.7) | 16 (14.3)       | 27 (17.4)               | 4 (7.7)       | 0.230       |
| Performed            | 23 (7.2)  | 7 (6.3)        | 14 (9.0)                | 2 (3.8)       | 0.720       |
| SAVR                 |       |               |                        |               |
| Planned              | 100 (31.3) | 27 (24.1)      | 48 (31.0)               | 25 (48.1)     | 0.002       |
| Performed            | 61 (19.1) | 16 (14.3)      | 26 (16.8)               | 19 (36.5)     | 0.001       |
On the contrary, the potential turnover of patients undergoing patients to the wait list does not result in a higher throughput. Capacity for SAVR in a given hospital and merely adding bidities. A potential explanation is that there is a contraindicated (such as very elderly patients with comorbidities). A potential explanation is that there is a fixed capacity for SAVR in a given hospital and merely adding patients to the wait list does not result in a higher throughput. On the contrary, the potential turnover of patients undergoing interventions being pursued was also seen during the FDR phase, although this did not achieve statistical significance. This study provides proof of concept and offers the possibility that similar benefit could be gained by automated communications containing the same information and sent to the referrer (for example, by e-mail generated by the echocardiographer or the machine itself), to minimize delays.

The reasons for the difference in the effect of FDR on the rate of delivery of TAVR and SAVR are unknown but could possibly relate to the increased awareness of the role of TAVR in patients who are at high surgical risk or for whom surgery is contraindicated (such as very elderly patients with comorbidities). A potential explanation is that there is a fixed capacity for SAVR in a given hospital and merely adding patients to the wait list does not result in a higher throughput. On the contrary, the potential turnover of patients undergoing TAVR may be more flexible because it requires fewer resources and allows for a higher rate of AVR performance and a substantial shortening of the time to intervention. While an increase in TAVR performance capacity may contribute to this, it is unlikely to have a played a role in our setting because enrollment in each institution was limited to 3 months for observation A, 6 months for FDR, and 3 months for observation B. The fact that there are differences between countries included in this study suggest that other factors may also have an impact, which could include issues of logistics and infrastructure that appear to be much less of a problem in Germany and Italy than in the United Kingdom. All the centers involved in this study had the capability of delivering SAVR and TAVR, and it is not known whether the effect of FDR might be different in centers without direct access to these interventions. Given the adverse effect that

### Table 4. Time to Intervention: Country-Specific Analysis

|                | Total        | Observation A | FDR | Observation B | P vs Phase A |
|----------------|--------------|---------------|-----|---------------|--------------|
|                | Mean±SD      | Mean±SD       |     | Mean±SD       |              |
| Total          | 33.0±34.7    | 36.45±37.6    | 29.9±33.0 | 0.002 | 34.0±33.0     | 0.816        |
| AVR            | 29.2±34.2    | 35.5±39.1     | 24.8±31.2 | <0.001 | 28.4±30.5     | 0.182        |
| SAVR           | 40.7±34.5    | 38.3±34.2     | 40.4±34.4 | 0.798 | 44.5±35.1     | 0.091        |
| Germany        |              |               |     |               |              |
| AVR            | 24.6±29.2    | 23.6±25.7     | 23.1±30.2 | 0.119 | 28.5±32.1     | 0.347        |
| TAVR           | 21.4±28.2    | 22.2±25.6     | 17.4±28.4 | 0.004 | 26.3±30.6     | 0.373        |
| SAVR           | 40.3±29.1    | 29.5±25.7     | 47.1±25.9 | 0.003 | 47.7±39.0     | 0.072        |
| UK             |              |               |     |               |              |
| AVR            | 50.9±41.5    | 54.2±45.5     | 47.0±35.4 | 0.615 | 50.4±41.8     | 0.606        |
| TAVR           | 53.2±42.9    | 60.5±50.9     | 50.3±37.8 | 0.605 | 47.9±37.3     | 0.410        |
| SAVR           | 47.2±39.2    | 45.0±35.0     | 39.3±28.6 | 0.667 | 53.8±47.8     | 0.968        |
| France         |              |               |     |               |              |
| AVR            | 22.0±26.2    | 22.2±22.1     | 22.9±29.5 | 0.242 | 18.3±20.0     | 0.209        |
| TAVR           | 20.7±25.8    | 23.4±20.9     | 21.5±29.8 | 0.078 | 14.4±15.5     | 0.053        |
| SAVR           | 23.6±26.7    | 21.2±23.3     | 24.7±29.3 | 0.965 | 25.5±25.4     | 0.672        |
| Italy          |              |               |     |               |              |
| AVR            | 35.9±34.7    | 54.8±44.7     | 29.1±30.2 | <0.001 | 26.1±15.6     | 0.005        |
| TAVR           | 35.1±35.1    | 53.5±44.0     | 26.7±27.3 | <0.001 | 23.8±20.1     | <0.007       |
| SAVR           | 37.7±33.9    | 59.1±48.4     | 35.8±37.3 | 0.071 | 28.3±9.3      | 0.115        |
| Others         |              |               |     |               |              |
| AVR            | 62.8±34.8    | 65.3±41.3     | 60.4±33.7 | 0.886 | 64.9±28.1     | 0.820        |
| TAVR           | 60.6±41.0    | 72.2±58.8     | 53.9±25.4 | 0.786 | 50.5±20.5     | 0.693        |
| SAVR           | 63.7±32.4    | 61.5±28.9     | 63.4±36.8 | 0.668 | 66.3±28.8     | 0.676        |

Comparisons were analyzed using Mann–Whitney U test. No adjustment for multiple testing was made, because the analyses are meant to explore the country-specific effect, but with lower statistical power compared with the main analysis. AVR indicates aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
delays can have on outcomes for patients with severe AS (as illustrated by the mortality rate of 6% within 3 months noted across each phase of the study), these results suggest that additional measures may be necessary to further reduce delays in the delivery of intervention.27

There were limitations to the IMPULSE registry. As an observational, cross-sectional study, the outcomes after valve intervention beyond 3 months were not recorded. Furthermore, although treatment decisions were documented, the actual treatment that each patient underwent may have differed. Finally, despite a total number of patients of n=2171, the study was not powered to detect a difference in outcomes such as mortality. Future study at the population level will determine whether FDR altered appropriateness of intervention. The strengths of the IMPULSE registry include its prospective design and that it is the largest prospective registry to date that documents clinical characteristics and management of contemporary patients.

Conclusions

In conclusion, a significant proportion of patients diagnosed with severe AS on echocardiography wait >3 months from time of diagnosis to intervention. This delay to intervention occurred despite the majority being symptomatic and mostly with severe limitation. A simple, low-cost FDR process may improve treatment pathways for patients diagnosed with severe AS, by increasing the rate of intervention performed within 3 months and decreasing the time to TAVR. Although the effect of FDR was seen, the data from this study also highlighted differences in the delivery of aortic valve intervention to patients, with many more experiencing delay in the United Kingdom compared with Germany. Although FDR did not alter the overall rate of intervention, this process could be improved and has the potential to reduce perioperative and postoperative morbidity, while decreasing the number of patients dying on the waiting list for AVR. Future studies are now needed to formally demonstrate the impact of FDR on outcome.

Acknowledgments

Data were captured using the s4trials Software provided by Software for Trials Europe GmbH, Berlin, Germany.

Author Contributions

Frey, Steeds, Messika-Zeitoun, Kurucova, Thoenes, and Bramlage were involved in the conception and design of the study. Steeds, Lutz, and Bramlage drafted the manuscript and all other authors revised the article for important intellectual content. All authors gave final approval of the version to be published.

Sources of Funding

This work was supported by a research grant provided by Edwards Lifesciences (Nyon, Switzerland) to the Sponsor, the Institute for Pharmacology and Preventive Medicine (IPPMed, Cloppenburg, Germany).

Disclosures

Bramlage has received research funding for the present project and honoraria for consultancy from Edwards Lifesciences. Frey, Steeds, and Messika-Zeitoun have received honoraria for advisory board meetings and Rudolph speakers’ honoraria from Edwards Lifesciences. The institutions of these 3 and those of the remaining authors representing study centers have received funding for employing a study nurse. The remaining authors have no disclosures to report.

Authors’ Affiliations

From the Queen Elizabeth Hospital & Institute of Cardiovascular Sciences, University of Birmingham, UK (R.P.S.); Department of Cardiology and Angiology, University of Kiel, Germany (M.L., N.F.); James Cook Hospital, Middlesbrough, UK (J.T.); Interventional Cardiology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (A.S.); Cardiology Department I, University Clinic Mainz, Germany (E.S.); Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.M.); Department of Cardiovascular Surgery, Second Faculty of Medicine, Charles University, Prague, Czech Republic (J.M.); Department of Cardiothoracic Surgery, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy (M.A.); Department of Cardiology, University of Cologne Heart Center, Cologne, Germany (T.K.R.); St Bartholomew’s Hospital, London, UK (G.L.); University of Bari, Italy (A.S.B.); Krankenhaus der Barmherzigen Brüder Trier, Germany (K.E.H.); University of Turin, Italy (A.C.); 4th Medical Department, Hietzing Hospital, Vienna, Austria (G.D.-K.); Herzkatheterlabor Nymphenburg and Department of Cardiology, University of Munich, Germany (J.R.); Division of Cardiology and URT CNR of IFC, University Magna Graecia, Catanzaro, Italy (C.I.); Sapienza University of Rome, Italy (M.M.); Centre Hospital d’Annecy, France (L.B.); German Centre for Cardiovascular Research (DZHK), University Heart Center & Charité, Berlin, Germany (A.L.); Department of Cardiology, University Hospital Erlangen, Germany (M.A.); University of Amsterdam, Netherlands (B.J.B.); Institute for Pharmacology and Preventive Medicine, Cloppenburg,
References

1. Eveborn GW, Schirmer H, Heggenol G, Lunde P, Rasmussen K. The evolving epidemiology of valvular aortic stenosis. The Tromso study. Heart. 2013;99:396–400.

2. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodrigue Munoz D, Rosenhek R, Sjogren J, Tomos Mas P, Vahanian A, Watther T, Wendler O, Windecker S, Zamorano JL. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791.

3. Otto CM, Kumbhani DJ, Alexander KP, Calhoon JH, Desai MY, Kaul S, Lee JC, Ruiz CE, Vassilieva CM. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017;69:1313–1346.

4. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrell TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Tajkkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42: S1–S44.

5. Nishiuma RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD, Members AATF. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129: e521–e643.

6. Iung B, Baron G, Butchart EG, Delahaye F, Gohtike-Barwol C, Levarg OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1233–1241.

7. Freed BH, Sugeng L, Furlong K, Mor-Avi V, Raman J, Jeevanandam V, Lang RM. Reasons for nonadherence to guidelines for aortic valve replacement in patients with severe aortic stenosis and potential solutions. Am J Cardiol. 2010;105:1339–1342.

8. Heuvelman HJ, van Geldorp MW, Kappetein AP, Geleijnse ML, Galemwa TW, Bogers AJ, Takkenberg JJ. Clinical course of patients diagnosed with severe aortic stenosis in the Rotterdam area: insights from the AVARJN study. Neth Heart J. 2012;20:487–493.

9. Chan RH, Shaw JL, Hauser TH, Markson LJ, Manning WJ. Guideline adherence for echocardiographic follow-up in outpatients with at least moderate valvular disease. J Am Soc Echocardiogr. 2015;28:795–801.

10. Ahmed A, Sorajja P, Garberich RF, Farivar RS, Harris KM, Gossel M. Association of guideline adherence for serial evaluations with survival and adverse clinical events in patients with asymptomatic severe aortic stenosis. JAMA Cardiol. 2017;2:1141–1146.

11. Malaisrie SC, McDonald E, Kruse J, Li Z, McGee EC Jr, Abicht TO, Russell H, McCarthy RH, Andrei AC. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014;98:1564–1570; discussion 1570–1561.

12. Lund O, Nielsen TT, Emmertsen K, Flo C, Rasmussen B, Jensen FT, Pilegaard HK, Kristensen LH, Hansen OK. Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis. Thorac Cardiovasc Surg. 1996;44:289–295.

13. Dziadzio V, Clavel MA, Dziadzio M, Medina-Inojosa JR, Michelena H, Maalouf J, Nikomo V, Thapa P, Enrezigue-Sarano M. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391:960–969.

14. Frey N, Steeds RP, Serra A, Schulz E, Baldus S, Lutz M, Pohimsan C, Kurucova M, Bramlage P, Messika-Zeitoun D. Quality of care assessment and improvement in aortic stenosis—rationale and design of a multicentre registry (IMPULSE). BMC Cardiovasc Disord. 2017;17:15.

15. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F Jr, Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372–392.

16. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.

17. Iung B, Messika-Zeitoun D, Cachier A, Delahaye F, Baron G, Tornos P, Gohlke-Barton C, Boersma E, Ravaud P, Vahanian A. Actual management of patients with asymptomatic aortic valve disease: how practice fits with guidelines. Am Heart J. 2007;153:696–703.

18. Schwarz F, Baumann P, Manthey J, Hoffmann M, Schuler G, Mehmel HC, Schmitz W, Kubler W. The effect of aortic valve replacement on survival. Circulation. 1982;66:1105–1110.

19. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J. 1988;9(Suppl E):57–64.

20. Rosenhek R, Zilberszack R, Schemper M, Czerny M, Mundigler G, Graf S, Berger-Klein J, Grimm M, Gabriel H, Maurer G. Natural history of very severe aortic stenosis. Circulation. 2010;121:151–156.

21. Lancellotti P, Rosenhek R, Pibarat P, Iung B, Otto CM, Tornos P, Donal E, Prendergast B, Mage J, La Cannina G, Pierard LA, Maurer G. ESC Working Group on Valvular Heart Disease position paper–heart valve clinics: organization, structure, and experiences. Eur Heart J. 2013;34:1597–1606.

22. Chambers JB, Ray S, Prendergast B, Taggart D, Westaby S, Grothier L, Arden C, Wilson J, Campbell B, Sandoe J, Gohlke-Barton C, Mestres CA, Rosenhek R, Otto C. Specialist valve clinics: recommendations from the British Heart Valve Society working group on improving quality in the delivery of care for patients with heart valve disease. Heart. 2013;99:1714–1716.

23. Zilberszack R, Lancellotti P, Gilon D, Gabriel H, Schemper M, Maurer G, Massetti M, Rosenhek R. Role of a heart valve clinic programme in the management of patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. 2017;18:134–144.

24. Tagguu W, Topham A, Hart L, Carri-White G, Sulke N, Patel NR, Lloyd G. A cardiac sonographer led follow up clinic for heart valve disease. Int J Cardiol. 2009;132:240–243.

25. Shojaog A, Ranji SR, Shay LK, Charo LN, Lai JC, Rushakoff RJ, R McDonald KM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies [Vol. 1: series overview and methodology]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2004. Available at: https://www.ncbi.nlm.nih.gov/books/NBK43908/.

26. Walsh JM, McDonald KM, Shojaog A, Sundaram V, Nayak S, Lewis R, Goldstein DK, Goldstein MK. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44:646–657.

27. Wijeyasundera HC, Wong WW, Bennell MC, Femes SE, Radhakrishnan S, Peterson M, Ko DT. Impact of wait times on the effectiveness of transcatheter aortic valve replacement in severe aortic valve disease: a discrete event simulation model. Can J Cardiol. 2014;30:1162–1169.
SUPPLEMENTAL MATERIAL
Figure S1. Country specific analysis - Proportion of AVR (total), TAVR or SAVR planned within 3 months during the three study phases.

AVR, aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
Figure S2. Country specific analysis - Proportion of AVR (total), TAVR or SAVR performed within 3 months during the three study phases.

AVR, aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
Figure S3. Country specific analysis (Exclusion of countries) – Time to intervention.

FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.